DOC Pharma has been a key player in the Italian pharmaceutical sector since 1996. With an IQVIA 2023 ex-factory revenue of €299 million, DOC ranks eighth in value among pharmaceutical companies in Italy and second in the Class A generic drug market (IQVIA data). DOC is also among the top five companies in the generic drug sector by revenue, holding a market share of approximately 19%. Over the years, we have embarked on a path of growth and expansion—through acquisitions and process innovation—broadening our coverage across multiple therapeutic areas and offering a diverse range of healthcare solutions. This has strengthened our role in making healthcare accessible to all. DOC has consistently stood out for its commitment to excellence, positioning itself as a trusted partner for doctors, pharmacists, and millions of patients—empowering them to make better, more informed choices. Because the choices we make every day shape who we become.
1996